Vascular disease and lipids in diabetes

被引:37
作者
Garber, AJ
机构
[1] Baylor Coll Med, Dept Med, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Biochem, Houston, TX 77030 USA
[3] Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA
[4] Methodist Hosp, Dept Diabet Endocrinol & Metab, Houston, TX 77030 USA
关键词
D O I
10.1016/S0025-7125(05)70030-4
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Patients with diabetes mellitus are particularly susceptible to morbidity and mortality resulting from cardiovascular diseases, especially atherosclerosis. Diabetes and coronary heart disease share many of the same risk factors, such as disorders of lipid metabolism (hypercholesterolemia, hypertriglyceridemia, low levels of high-density lipoprotein [HDL] cholesterol) and hypertension. Although the exact mechanisms responsible for accelerated atherogenesis in patients with diabetes are not completely understood, an important role may he Flayed by increased glycosylation of lipoproteins. Other factors involved in the development of cardiovascular disease in diabetic patients include insulin resistance, endothelial dysfunction, and the presence of a small, dense low-density lipoprotein (LDL phenotype B). The management of lipid abnormalities in diabetic patients always begins with weight loss, proper diet, exercise, and glycemic control; however, it is clear that some patients will require aggressive Lipid-lowering therapy in addition to life-style measures.
引用
收藏
页码:931 / +
页数:19
相关论文
共 100 条
[1]   THE IMPACT OF DIABETES ON SURVIVAL FOLLOWING MYOCARDIAL-INFARCTION IN MEN VS WOMEN [J].
ABBOTT, RD ;
DONAHUE, RP ;
KANNEL, WB ;
WILSON, PWF .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1988, 260 (23) :3456-3460
[2]  
ABIRU T, 1990, RES COMMUN CHEM PATH, V68, P13
[3]   Cardiovascular events and correlates in the Veterans Affairs diabetes feasibility trial - Veterans Affairs Cooperative Study on gylcemic control and complications in type II diabetes [J].
Abraira, C ;
Colwell, J ;
Nuttall, F ;
Sawin, CT ;
Henderson, W ;
Comstock, JP ;
Emanuele, NV ;
Levin, SR ;
Pacold, I ;
Lee, HS ;
Silbert, CK ;
Cxypoliski, R ;
Vasquez, M ;
Kernan, D ;
Niewoehner, C ;
Backes, M ;
Bradley, M ;
Bradley, M ;
Crow, R ;
Rubino, F ;
Bushnell, D ;
Pfeifer, M ;
Service, FJ ;
Howard, B ;
Chew, E ;
Hoogwerf, B ;
Seigel, D ;
Clark, CM ;
Olefsky, JM ;
Porte, D ;
Sussman, KE ;
Johnson, N ;
Christine, B ;
Tir, K ;
Sather, M ;
Day, P ;
Morgan, N ;
Deykin, D ;
Gold, J ;
Huang, P .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (02) :181-188
[4]  
*AM DIAB ASS, 1996, DIABETES CARE S1, V19, pS96
[5]  
Amer Diabet Assoc, 1998, DIABETES CARE, V21, P179
[6]  
[Anonymous], 1989, DIABETES CARE, V12, P573
[7]   Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone [J].
Antonucci, T ;
Whitcomb, R ;
McLain, R ;
Lockwood, D .
DIABETES CARE, 1997, 20 (02) :188-193
[8]   RELATION OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND TRIGLYCERIDES TO INCIDENCE OF ATHEROSCLEROTIC CORONARY-ARTERY DISEASE (THE PROCAM EXPERIENCE) [J].
ASSMANN, G ;
SCHULTE, H .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (07) :733-737
[9]  
ASSMANN G, 1991, ATHER REV, V22, P51
[10]  
AUSTIN MA, 1988, JAMA-J AM MED ASSOC, V260, P1917